A Study of CC312 for Relapsed/Refractory Autoimmune Diseases

CC312 is administered twice weekly (BIW) on Day 1 and Day 4 of each week for a 4-week treatment period. After Day 28, subsequent dosing (including the decision to continue treatment, dosing frequency, and treatment duration) will be determined based on the subject's clinical response and B-cell depletion status. The maximum planned treatment period is 24 weeks, followed by a follow-up phase.